Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi… - European heart …, 2020 - academic.oup.com
Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of
worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We …
worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We …
[PDF][PDF] Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi… - European Heart …, 2020 - scienceopen.com
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy Page 1 Effects
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
[PDF][PDF] Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi… - European Heart …, 2020 - pdfs.semanticscholar.org
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy Page 1 Effects
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
[HTML][HTML] Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi, L Køber… - European Heart …, 2020 - ncbi.nlm.nih.gov
Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
[PDF][PDF] Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi, L Køber… - European Heart …, 2020 - core.ac.uk
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy Page 1 Effects
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
[PDF][PDF] Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi, L Køber… - European Heart …, 2020 - dapatrial.org
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy Page 1 Effects
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
of dapagliflozin in DAPA-HF according to background heart failure therapy Kieran F. Docherty …
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi… - European Heart …, 2020 - research.regionh.dk
AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi, L Køber… - European Heart …, 2020 - eprints.gla.ac.uk
Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi, L Køber… - European Heart …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Aims</jats: title>< jats: p> In the
DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure …
DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure …
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi… - European heart …, 2020 - pubmed.ncbi.nlm.nih.gov
Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …